The 3rd U.S. Circuit Court of Appeals on July 18 gave Merck & Co. Inc. shareholders a second chance to seek to use after-acquired information in their derivative suits against officer and directors for allegedly concealing the health risks of the painkiller Vioxx.
The court ruled that U.S. District Judge Stanley Chesler of the New Jersey District erred by refusing to consider new information, which resulted from a consensual stipulation, in dismissing the suit.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
